Breaking News

Amgen Names Global Regulatory and Safety SVP

May 13, 2014

Galson responsible for all regulatory and patient safety functions

Steven K. Galson, M.D., M.P.H., has been appointed senior vice president, Global Regulatory Affairs and Safety at Amgen, effective May 19. Dr. Galson will be responsible for all regulatory and patient safety functions across Amgen, reporting to Sean E. Harper, M.D., executive vice president of R&D.
Dr. Galson joined the company in October 2010 as vice president of Global Regulatory Affairs. Prior to Amgen, he served as senior vice president for Civilian Health Operations and chief health scientist at Science Applications International Corp.
His 23-year career in the U.S. Public Health Service included acting U.S. Surgeon General during the Bush-Obama transition in 2009, and was the acting Assistant Secretary for Health, and deputy director and director of the FDA Center for Drug Evaluation and Research.
"Steven has led Amgen's regulatory team for the past three and a half years, and his success in this critical role has prepared him for these expanded responsibilities," said Dr. Harper. "Steven's deep and broad experience in both the public and private health sectors makes him an excellent choice to manage the unprecedented number of regulatory filings that Amgen has planned, and to lead our effort to continually evaluate and communicate the safety profile of our medicines."

Related Compliance:

blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus